2026 ICD-10-CM Diagnosis Code E72.01Cystinuria
ICD-10-CM Codes›E00–E89›E70-E88›E72
- Billable — Valid for Submission
- Chronic Condition
E72.01 is a billable ICD-10-CM diagnosis code for cystinuria. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026). Coders also document this condition as atypical hypotonia cystinuria syndrome. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Other specified and unspecified nutritional and metabolic disorders.
Code Identity
Code Classification
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Atypical hypotonia cystinuria syndrome
- Cystinuria
- Cystinuria, type 1
- Cystinuria, type 2
- Cystinuria, type 3
- Hypotonia cystinuria syndrome
- Isolated cystinuria
Index to Diseases and InjuriesGuidance
Alphabetical index entries that point to this code.
- Cystinuria - E72.01
- Disorder (of) - See Also: Disease;
- cystinuria - E72.01
- metabolism NOS - E88.9
- cystinuria - E72.01
- cystine - E72.01
External Cause of Injuries IndexGuidance
References for this code in the External Cause of Injuries Index.
- Cystinuria
- Disorder(of)
- amino-acid
- cystinuria
- Disorder(of)
- metabolism NOS
- cystinuria
- Hyperaminoaciduria
- cystine
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Cystinuria
an inherited disorder due to defective reabsorption of cystine and other basic amino acids by the proximal renal tubules. this form of aminoaciduria is characterized by the abnormally high urinary levels of cystine; lysine; arginine; and ornithine. mutations involve the amino acid transport protein gene slc3a1.Combined Methylmalonic Aciduria and Homocystinuria|Combined methylmalonic acidemia and homocystinuria due to defects in adenosylcobalamin and methylcobalamin synthesis
a genetically heterogeneous disorder of cobalamin (cbl; vitamin b12) metabolism due to loss of function mutations in the enzymes that synthesize the coenzymes adenosylcobalamin (adocbl) and methylcobalamin (mecbl). this is a subtype of methylmalonic acidemia that includes complementation groups cblc, cbld, cblf, cblj, cbll and cblx.Arakawa Syndrome II|Arakawa's Syndrome 2|Arakawa's Syndrome II|Homocystinuria-Megaloblastic Anemia, cblG Complementation Type|Methionine Synthase Deficiency|Methylcobalamin Deficiency, cblG Type|Tetrahydrofolate Methyltransferase Deficiency|Tetrahydrofolate Methyltransferase Deficiency
a rare autosomal dominant inherited metabolic disorder characterized by deficiency of the enzyme tetrahydrofolate-methyltransferase. it results in the abnormal metabolism of methylcobalamin. signs and symptoms include mental retardation, megaloblastic anemia, hypotonia, epilepsy, and hepatosplenomegaly.Cystinuria
an autosomal recessive inherited metabolic disorder caused by mutations in the slc3a1 and slc7a9 genes. it is characterized by deficient re-absorption of cystine in the proximal tubules of the kidney. it results in the formation of stones in the kidney, ureter, and urinary bladder.Homocystinuria
an autosomal recessive inherited metabolic disorder caused by mutations in the cbs, mthfr, mtr, and mtrr genes. it is characterized by abnormalities in the methionine metabolism and is associated with deficiency of cystathionine synthase. it results in the accumulation of homocysteine in the serum. it may affect the cardiovascular, musculoskeletal and the central nervous systems.Homocystinuria-Megaloblastic Anemia, cblE Complementation Type|HMAE|Methylcobalamin Deficiency, cblE Type
an autosomal recessive condition caused by mutation(s) in the mtrr gene, encoding methionine synthase reductase. it is characterized by homocystinuria and megaloblastic anemia.Methylmalonic Aciduria and Homocystinuria Type D Protein, Mitochondrial|C2orf25 Protein|MMADHC|Methylmalonic Aciduria, cblD Type, And Homocystinuria Protein|Uncharacterized Protein C2orf25, Mitochondrial
methylmalonic aciduria and homocystinuria type d protein, mitochondrial (296 aa, ~33 kda) is encoded by the human mmadhc gene. this protein plays a role in vitamin metabolism.Methylmalonic Aciduria and Homocystinuria, cblC Type
an autosomal recessive form of combined methylmalonic aciduria and homocystinuria, caused by mutation(s) in the mmachc gene, encoding methylmalonic aciduria and homocystinuria type c protein.Methylmalonic Aciduria and Homocystinuria, cblD Type|MAHCD
an autosomal recessive form of combined methylmalonic aciduria and homocystinuria, caused by mutation(s) in the mmadhc gene, encoding cobalamin trafficking protein cbld.Methylmalonic Aciduria and Homocystinuria, cblF Type|MAHCF
an autosomal recessive form of combined methylmalonic aciduria and homocystinuria, caused by mutation(s) in the lmbrd1 gene, encoding lysosomal cobalamin transport escort protein lmbd1.Methylmalonic Aciduria and Homocystinuria, cblJ Type|MAHCJ
an autosomal recessive form of combined methylmalonic aciduria and homocystinuria, caused by mutation(s) in the abcd4 gene, encoding lysosomal cobalamin transporter abcd4.MMADHC Gene|MMADHC|MMADHC|Methylmalonic Aciduria (Cobalamin Deficiency) cblD Type, with Homocystinuria Gene
this gene is involved in vitamin metabolism.MMADHC wt Allele|C2orf25|CL25022|Chromosome 2 Open Reading Frame 25 Gene|HSPC161|Methylmalonic Aciduria (Cobalamin Deficiency) cblD Type, with Homocystinuria wt Allele|Methylmalonic Aciduria, cblD Type, and Homocystinuria Gene|My011|cblD
human mmadhc wild-type allele is located in the vicinity of 2q23.2 and is approximately 18 kb in length. this allele, which encodes methylmalonic aciduria and homocystinuria type d protein, mitochondrial, plays a role in the mediation of vitamin b12 metabolism. mutation of the gene is associated with some cases of homocystinuria, and methylmalonic aciduria.Cyanocobalamin Reductase / Alkylcobalamin Dealkylase|Alkylcobalamin:Glutathione S-Alkyltransferase|CblC|Cyanocobalamin Reductase (Cyanide-Eliminating)|EC 1.16.1.6|EC 2.5.1.15|MMACHC|Methylmalonic Aciduria and Homocystinuria Type C Protein
cyanocobalamin reductase / alkylcobalamin dealkylase (282 aa, ~32 kda) is encoded by the human mmachc gene. this protein is involved in cobalamin transport and the decyanation of cyanocob(iii)alamin (cyanocobalamin, cncbl) to yield cob(ii)alamin and cyanide and the dealkylation of alkylcob(iii)alamins using a thiolate of glutathione to generate cob(i)alamin and the corresponding glutathione thioether.MMACHC wt Allele|DKFZP564I122|Metabolism of Cobalamin Associated C wt Allele|Methylmalonic Aciduria (Cobalamin Deficiency) cblC Type, with Homocystinuria Gene|cblC
human mmachc wild-type allele is located in the vicinity of 1p34.1 and is approximately 13 kb in length. this allele, which encodes cyanocobalamin reductase / alkylcobalamin dealkylase protein, plays a role in cobalamin transport and the conversion of cyanocobalamin and alkylcobalamin to cobalamin. mutation of the gene is associated with methylmalonic aciduria and homocystinuria cblc type.
Patient EducationClinical
Kidney Stones
A kidney stone is a solid piece of material that forms in the kidney from substances in the urine. It may be as small as a grain of sand or as large as a pearl. Most kidney stones pass out of the body without help from a doctor. But sometimes a stone will not go away.
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert E72.01 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About E72.01Overview
Is E72.01 (Disorders of amino-acid transport) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report cystinuria on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What is the ICD-9 equivalent of E72.01?
Under the General Equivalence Mappings, cystinuria converts to ICD-9-CM 270.0 (amino-acid transport dis). The mapping is approximate, so confirm the match fits the documentation.
Footnotes
[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:
- The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
- The condition places limitations on self-care, independent living, and social interactions.
